Welcome to the UPF Digital Repository

Ellagic tcid as a Tool to limit the diabetes burden: updated evidence

Show simple item record

dc.contributor.author Amor, Antonio J.
dc.contributor.author Gómez Guerrero, Carmen
dc.contributor.author Ortega, Emilio
dc.contributor.author Sala Vila, Aleix
dc.contributor.author Lázaro, Iolanda
dc.date.accessioned 2021-02-19T08:00:06Z
dc.date.available 2021-02-19T08:00:06Z
dc.date.issued 2020
dc.identifier.citation Amor AJ, Gómez-Guerrero C, Ortega E, Sala-Vila A, Lázaro I. Ellagic acid as a tool to limit the diabetes burden: updated evidence. Antioxidants (Basel). 2020 Dec 3; 9(12): 1226. DOI: 10.3390/antiox9121226.
dc.identifier.issn 2076-3921
dc.identifier.uri http://hdl.handle.net/10230/46541
dc.description.abstract Oxidative stress contributes not only to the pathogenesis of type 2 diabetes (T2D) but also to diabetic vascular complications. It follows that antioxidants might contribute to limiting the diabetes burden. In this review we focus on ellagic acid (EA), a compound that can be obtained upon intestinal hydrolysis of dietary ellagitannins, a family of polyphenols naturally found in several fruits and seeds. There is increasing research on cardiometabolic effects of ellagitannins, EA, and urolithins (EA metabolites). We updated research conducted on these compounds and (I) glucose metabolism; (II) inflammation, oxidation, and glycation; and (III) diabetic complications. We included studies testing EA in isolation, extracts or preparations enriched in EA, or EA-rich foods (mostly pomegranate juice). Animal research on the topic, entirely conducted in murine models, mostly reported glucose-lowering, antioxidant, anti-inflammatory, and anti-glycation effects, along with prevention of micro- and macrovascular diabetic complications. Clinical research is incipient and mostly involved non-randomized and low-powered studies, which confirmed the antioxidant and anti-inflammatory properties of EA-rich foods, but without conclusive results on glucose control. Overall, EA-related compounds might be potential agents to limit the diabetes burden, but well-designed human randomized controlled trials are needed to fill the existing gap between experimental and clinical research.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/4.0/
dc.title Ellagic tcid as a Tool to limit the diabetes burden: updated evidence
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/antiox9121226
dc.subject.keyword Diabetic complications
dc.subject.keyword Ellagic acid
dc.subject.keyword Glucose metabolism
dc.subject.keyword Inflammation
dc.subject.keyword Oxidative stress
dc.subject.keyword Type 2 diabetes
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

In collaboration with Compliant to Partaking